Eurofins clocked a better-than-expected performance in Q3 FY20, lifted by its broad COVID-19 testing portfolio and a gradual recovery in the core operations. While the management has left its FY20 and FY21 objectives unchanged, it expects to beat them significantly, as testing demand is likely to be sustained in the near-term. Dividend payments are also expected to resume next year.
26 Oct 2020
COVID-19 testing boosts Q3 revenue; more to come in Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
COVID-19 testing boosts Q3 revenue; more to come in Q4
Eurofins clocked a better-than-expected performance in Q3 FY20, lifted by its broad COVID-19 testing portfolio and a gradual recovery in the core operations. While the management has left its FY20 and FY21 objectives unchanged, it expects to beat them significantly, as testing demand is likely to be sustained in the near-term. Dividend payments are also expected to resume next year.